7.305
Precedente Chiudi:
$6.97
Aprire:
$7.13
Volume 24 ore:
93,407
Relative Volume:
1.16
Capitalizzazione di mercato:
$703.71M
Reddito:
$106.66M
Utile/perdita netta:
$15.16M
Rapporto P/E:
78.13
EPS:
0.0935
Flusso di cassa netto:
$6.37M
1 W Prestazione:
+3.47%
1M Prestazione:
-8.46%
6M Prestazione:
-4.13%
1 anno Prestazione:
-26.88%
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Nome
Gyre Therapeutics Inc
Settore
Industria
Telefono
(858) 567-7770
Indirizzo
12770 HIGH BLUFF DRIVE, SAN DIEGO
Confronta GYRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
GYRE
Gyre Therapeutics Inc
|
7.305 | 671.44M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | Jefferies | Buy |
| 2025-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Gyre Therapeutics Inc Borsa (GYRE) Ultime notizie
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7%Time to Sell? - MarketBeat
Gyre Therapeutics, Inc. Announces Completion of the Pre-NDA Meeting on the Regulatory Strategy for F351 - MarketScreener
GNI Group’s F351 Secures Path Toward Conditional Approval and Priority Review in China - TipRanks
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpShould You Buy? - MarketBeat
Gyre Therapeutics stock soars after positive pre-NDA meeting in China - Investing.com
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Gyre Pharmaceuticals advances liver fibrosis drug toward China approval By Investing.com - Investing.com Canada
Gyre Therapeutics Announces Pre-NDA Meeting Success for Hydronidone - TradingView — Track All Markets
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting - The Manila Times
Experimental liver fibrosis drug in China moves closer to patient use - Stock Titan
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Rating of "Hold" by Analysts - MarketBeat
Gyre Therapeutics president sells $45,380 in stock - MSN
Undiscovered Gems in the US Market to Explore This December 2025 - Yahoo Finance
Published on: 2025-12-21 18:19:37 - Улправда
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6% – Time to Sell? - Defense World
Will Gyre Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Breakouts & Low Drawdown Investment Strategies - Улправда
Gyre Therapeutics Earnings Notes - Trefis
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6%Time to Sell? - MarketBeat
Why Gyre Therapeutics Inc. stock remains on buy lists2025 Trading Recap & Long-Term Capital Growth Strategies - Улправда
Levels Update: Is Gyre Therapeutics Inc. stock vulnerable to regulatory risks2025 Major Catalysts & Weekly Momentum Picks - Улправда
Will Gyre Therapeutics Inc. stock deliver consistent dividends2025 Market WrapUp & Reliable Price Action Trade Plans - Улправда
Does Gyre Therapeutics Inc. stock trade at a discount to peers2025 Geopolitical Influence & AI Driven Price Forecasts - Улправда
Gyre therapeutics president Ma Songjiang sells $45,434 in stock - MSN
US High Growth Tech Stocks to Watch - Yahoo Finance
Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 5.9%Should You Sell? - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of “Hold” from Brokerages - Defense World
GNI Group’s Subsidiary Completes Enrollment for Key Clinical Trial - MSN
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 2.3%Time to Buy? - MarketBeat
Gyre Therapeutics (GYRE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Gyre Therapeutics Stock Built to Withstand a Pullback? - Trefis
Regarding video postings related to our company group information on some social networking services (SNS). - 富途牛牛
Published on: 2025-11-27 08:38:09 - moha.gov.vn
Is Gyre Therapeutics Inc a good long term investmentMarket Depth Overview & Free Unmatched Market Performance - earlytimes.in
Is Gyre Therapeutics Inc. stock a dividend growth opportunity2025 Short Interest & Real-Time Volume Triggers - newser.com
Is Gyre Therapeutics Inc. stock dividend yield sustainableJuly 2025 Closing Moves & Safe Entry Point Identification - newser.com
What drives Gyre Therapeutics Inc stock priceMarket Capitalization Trends & Free Triple Digit Wealth Increase - earlytimes.in
Will Gyre Therapeutics Inc. stock return to pre crisis levelsLong Setup & Low Risk High Win Rate Picks - newser.com
Should I hold or sell Gyre Therapeutics Inc. stock in 2025July 2025 Final Week & Verified Technical Signals - newser.com
Why Gyre Therapeutics Inc. stock remains on watchlistsMarket Activity Report & Weekly Chart Analysis and Guides - newser.com
What recovery options are there for Gyre Therapeutics Inc.2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Can Gyre Therapeutics Inc. stock sustain institutional interest2025 Biggest Moves & Smart Money Movement Tracker - newser.com
How Gyre Therapeutics Inc. stock performs in interest rate cyclesMarket Activity Recap & Daily Volume Surge Signals - newser.com
Is Gyre Therapeutics Inc. stock entering bullish territoryTrade Entry Summary & Long-Term Safe Investment Ideas - newser.com
Gyre Therapeutics Inc Azioni (GYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):